Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer-fighting drugs might also stop malaria early

26.08.2014

Scientists searching for new drugs to fight malaria have identified a number of compounds -- some of which are currently in clinical trials to treat cancer -- that could add to the anti-malarial arsenal.

Duke University assistant professor Emily Derbyshire and colleagues identified more than 30 enzyme-blocking molecules, called protein kinase inhibitors, that curb malaria before symptoms start.

By focusing on treatments that act early, before a person is infected and feels sick, the researchers hope to give malaria –- especially drug-resistant strains –- less time to spread.

The findings appear online and are scheduled to appear in a forthcoming issue of the journal ChemBioChem.

... more about:
»ChemBioChem »blood »drugs »liver »malaria »parasites »symptoms

Malaria is caused by a single-celled parasite called Plasmodium that spreads from person to person through mosquito bites. When an infected mosquito bites, parasites in the mosquito's saliva first make their way to the victim's liver, where they silently grow and multiply into thousands of new parasites before invading red blood cells -- the stage of the disease that triggers malaria's characteristic fevers, headaches, chills and sweats.

Most efforts to find safe, effective, low-cost drugs for malaria have focused on the later stage of the infection when symptoms are the worst. But Derbyshire and her team are testing chemical compounds in the lab to see if they can identify ones that inhibit malaria during the short window when the parasite is still restricted to the liver, before symptoms start.

One of the advantages of her team's approach is that focusing on the liver stage of the malaria lifecycle -- before it has a chance to multiply -- means there are fewer parasites to kill.

Using a strain of malaria that primarily infects rodents, Derbyshire and Jon Clardy of Harvard Medical School tested 1,358 compounds for their ability to keep parasites in the liver in check, both in test tubes and in mice.

"It used to be that researchers were lucky if they could identify one or two promising compounds at a time; now with advances in high-throughput screening technology we can explore thousands at once and identify many more," said Derbyshire, an assistant professor in the Departments of Chemistry and Molecular Genetics and Microbiology at Duke.

Focusing on a particular group of enzyme-blocking compounds called protein kinase inhibitors, they identified 31 compounds that inhibit malaria growth without harming the host. Several of the compounds are currently in clinical trials to treat cancers like leukemia and myeloma.

The same compounds that stopped the stage of malaria that lurks in the liver also worked against the stage that lives in the blood.

Malaria-free mice that received a single dose before being bitten by infected mosquitos were able to avoid developing the disease altogether.

Medicines for malaria have been around for hundreds of years, yet the disease still afflicts more than 200 million people and claims hundreds of thousands of lives each year, particularly in Asia and Africa. Part of the reason is malaria's ability to evade attack. One of the most deadly forms of the parasite, Plasmodium falciparum, has already started to outsmart the world's most effective antimalarial drug, artemisinin, in much of southeast Asia. Infections that used to clear up in a single day of treatment now take several days.

Diversifying the antimalarial arsenal could also extend the lifespan of existing drugs, since relying less heavily on our most commonly used weapons gives the parasite fewer opportunities to develop resistance, Derbyshire said.

Another advantage is that the compounds they tested suppress multiple malaria proteins at once, which makes it harder for the parasites to develop ways around them.

"That makes them like a magic bullet," she said.

###

The research was supported by Duke University, Harvard Medical School and the National Institutes of Health (Grant Number: GM099796)

CITATION: "Chemical interrogation of the malaria kinome," Derbyshire, E. and Clardy, J., et al. ChemBioChem, 2014. http://dx.doi.org/10.1002/cbic.201400025

Robin Ann Smith | Eurek Alert!
Further information:
http://www.duke.edu

Further reports about: ChemBioChem blood drugs liver malaria parasites symptoms

More articles from Health and Medicine:

nachricht Nanotubes are beacons in cancer-imaging technique
23.05.2016 | Rice University

nachricht More light on cancer
20.05.2016 | Lomonosov Moscow State University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Atomic precision: technologies for the next-but-one generation of microchips

In the Beyond EUV project, the Fraunhofer Institutes for Laser Technology ILT in Aachen and for Applied Optics and Precision Engineering IOF in Jena are developing key technologies for the manufacture of a new generation of microchips using EUV radiation at a wavelength of 6.7 nm. The resulting structures are barely thicker than single atoms, and they make it possible to produce extremely integrated circuits for such items as wearables or mind-controlled prosthetic limbs.

In 1965 Gordon Moore formulated the law that came to be named after him, which states that the complexity of integrated circuits doubles every one to two...

Im Focus: Researchers demonstrate size quantization of Dirac fermions in graphene

Characterization of high-quality material reveals important details relevant to next generation nanoelectronic devices

Quantum mechanics is the field of physics governing the behavior of things on atomic scales, where things work very differently from our everyday world.

Im Focus: Graphene: A quantum of current

When current comes in discrete packages: Viennese scientists unravel the quantum properties of the carbon material graphene

In 2010 the Nobel Prize in physics was awarded for the discovery of the exceptional material graphene, which consists of a single layer of carbon atoms...

Im Focus: Transparent - Flexible - Printable: Key technologies for tomorrow’s displays

The trend-forward world of display technology relies on innovative materials and novel approaches to steadily advance the visual experience, for example through higher pixel densities, better contrast, larger formats or user-friendler design. Fraunhofer ISC’s newly developed materials for optics and electronics now broaden the application potential of next generation displays. Learn about lower cost-effective wet-chemical printing procedures and the new materials at the Fraunhofer ISC booth # 1021 in North Hall D during the SID International Symposium on Information Display held from 22 to 27 May 2016 at San Francisco’s Moscone Center.

Economical processing

Im Focus: Trojan horses for hospital bugs

Staphylococcus aureus usually is a formidable bacterial pathogen. Sometimes, however, weakened forms are found in the blood of patients. Researchers of the University of Würzburg have now identified one mutation responsible for that phenomenon.

Staphylococcus aureus is a bacterium that is frequently found on the human skin and in the nose where it usually behaves inconspicuously. However, once inside...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Networking 4.0: International Laser Technology Congress AKL’16 Shows New Ways of Cooperations

24.05.2016 | Event News

Challenges of rural labor markets

20.05.2016 | Event News

International expert meeting “Health Business Connect” in France

19.05.2016 | Event News

 
Latest News

Rutgers scientists help create world's largest coral gene database

24.05.2016 | Earth Sciences

New technique controls autonomous vehicles on a dirt track

24.05.2016 | Information Technology

Programmable materials find strength in molecular repetition

24.05.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>